First, in septic shock, a secondary analysis of the Vasopressin and Septic Shock trial suggested that higher baseline levels of IL-3, IL-6, and CCL4 may identify patients as potential responders to glucocorticoids resulting in reduced mortality [33]. The gene discussed is IL6; the disease is septic shock.